William L. Ballhaus, Chairman, President & CEO of Mercury Systems (), sold common stock valued at approximately $15.7 million across multiple transactions on August 21 and August 24, 2026. These sales followed the exercise of stock options, with the proceeds primarily
Todd G. Schwartz, Chief Executive Officer, Director, and a 10% owner of OppFi Inc. (), purchased shares of the company’s Class A Common Stock on August 24, 2026. Mr. Schwartz acquired 3,475 shares at a weighted average price of $7.1455
Kelly Bodnar Battles, a Director at Arista Networks, Inc. (), sold 422 shares of the company’s common stock on August 21, 2026. The total value of the shares sold amounted to $79,057, with prices ranging from $184.7679 to $188.692 per share.
William Thomas Blackorby, VP, Chief Supply Chain Officer at Interface Inc (), recently sold 2,826 shares of the company’s common stock. The transaction, which occurred on August 19, 2026, totaled $110,807. The shares were sold at a price of $39.21
James Kuffner, Chief Technology Officer at Symbotic Inc. (), sold shares of the company’s Class A common stock totaling $160,421 on August 24, 2026. The shares were sold at an average price of $40.5926, with individual transactions ranging from $40.565
Edwin Roks, President and Chief Executive Officer of TTM Technologies Inc. (), purchased 10,000 shares of the company’s common stock on August 25, 2026. The shares were acquired at a weighted average price of $111.77 per share, with individual
Alan King, Group President of International Vehicle Payments at CORPAY, INC. (), sold 3,805 shares of the company’s common stock for a total value of $1,585,195. The transactions occurred on August 21, 2026, with prices ranging from $416.50 to $417.31 per
Tarun Arora, Chief Accounting Officer at RingCentral, Inc. (), sold 675 shares of the company’s Class A Common Stock on August 25, 2026. The shares were sold at a price of $67.45 per share, totaling $45,528 from the transaction. The
Rhodes R. Bobbitt, a director at Hilltop Holdings Inc. (), recently sold a total of 10,000 shares of the company’s common stock for approximately $388,000. The transactions occurred on August 21 and August 24, 2026, with shares sold at a
Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc. (), sold shares totaling over $1.45 million and exercised stock options on August 17 and 18, 2026. The transactions were conducted under a Rule 10b5-1 trading plan, which was
